Anders Berkenstam
Oprichter bij Axcentua Pharmaceuticals AB
Profiel
Anders Berkenstam is the founder of Axcentua Pharmaceuticals AB, which was founded in 2007.
He holds the title of Director & Chief Scientific Officer at the company.
Dr. Berkenstam also worked as an Associate Professor at Karolinska Institutet.
He obtained a doctorate degree from Karolinska Institutet.
Actieve functies van Anders Berkenstam
Bedrijven | Functie | Begin |
---|---|---|
Axcentua Pharmaceuticals AB
Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Oprichter | 17-09-2009 |
Eerdere bekende functies van Anders Berkenstam
Bedrijven | Functie | Einde |
---|---|---|
Karolinska Institutet | Corporate Officer/Principal | - |
Opleiding van Anders Berkenstam
Karolinska Institutet | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Axcentua Pharmaceuticals AB
Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Health Technology |